About
Intervacc AB is a Swedish biotechnology company developing recombinant protein fusion-based vaccines for animal health, focusing primarily on equine diseases such as strangles with its product Strangvac®. The company operates through subsidiaries Nordvacc Läkemedel and Mybac-Vettech and has an established sales organization active in the European animal health market.
Explore Intervacc AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.